E. Bottieau 18/12/2014 - info-ebola.be€¦ · WHO response team N Engl J Med 2014 . 13 EVD:...

Preview:

Citation preview

E. Bottieau

Avondseminarie ITG

18/12/2014

Introductie

On March 10, 2014, hospitals and public health services in Guéckédou and Macenta

alerted the Ministry of Health of Guinea about clusters of a mysterious disease

characterized by fever, severe diarrhea, vomiting, and an apparent high fatality

rate.

Yambuku, mission hospital, Zaire

Ebola epidemics in the past

602 cases 72% death

315 cases 81% death

425 cases 53% death

413 cases 51% death

Baize S et al. N Engl J Med 2014.

Ebola virus disease (EVD) epidemic in West Africa

March 2014: WHO alert

EVD epidemic in West Africa: initial transmission

Alert due to cluster of cases

March 2014

Baize S et al. N Engl J Med 2014.

Initial single case ! Dec 2013

Cumulative reported cases of EVD in Guinea, Liberia and Sierra Leone Mar 25-Dec 10, 2014 (n=17908)

EVD epidemic in West Africa: current situation

7

Ebolavirus: phylogenetic analysis “Fruit bat”

Carroll SA et al. J Virol 2013

Family Filoviridae

Zaire ebolavirus

Sudan ebolavirus

Bundibugyo ebol.

(Reston ebol.)

(Taï Forest ebol.)

8

Ebolavirus: viral structure “Fruit bat”

• Negative strand RNA virus

• Small genome (7 viral genes)

• Surface glycoprotein (GP)

• RNA Polymerase (L)

• 4 structural proteins

9

Ebolavirus: transmission “Fruit bat”

10

Ebolavirus: transmission “Fruit bat”

Human Human

11

EVD: pathogenesis

Ansart AA. J Autoimm 2014

12

EVD: event timeline “Fruit bat”

Inoculation (“challenge”)

Onset clinical symptoms

(Death)

Prepatent Symptomatic Recovery

5d (sd 4) 9d (sd 7)

7d (sd 5)

Early symptoms

% Fever 87 Fatigue 77 Vomiting 68 Diarrhea 66

% Cough 30 Dyspnea 23 Dysphagia 33 Sore throat 22 Bleeding 18 Confusion 13 Jaundice 10

Hosp. (Discharge)

16d (sd 6)

Late symptoms

WHO response team N Engl J Med 2014

13

EVD: clinical features and predictors of death

WHO response team N Engl J Med 2014

14

EVD: risk factors for death - age

Age: 0-5 years Age: 5-40 years Age: > 40 years

15

EVD: risk factors for death - EBOV load

Schieffelin JS et al. N Engl J Med 2014

16

EVD: viral detection over time in body fluids

17

EVD in the field: pictures MSF

18

EVD treatment: supportive care (Europe/USA)

19

EVD experimental treatments

Immunotherapy

Antivirals

Vaccines

Convalescent plasma Study Guinea: Jan 2015/ITG

Monoclonal antib. (Zmapp)

Equine polyclonal immunoglobulins

100% protective NHP/used in humans

Phase 1 planned in Apr 2015

Favipiravir (Toyama/Fuji)

Brincidofovir (Chimerix)

TKM-100802 (Tekmira)

AVI-7537 (Sarepta)

BCX 4430 (BioCryst)

NA; Study Guinea: Dec 2014 /INSERM

RNA anti-sense; phase 1 ongoing

RNA anti-sense; study NHP ongoing

NA; study NHP ongoing

NA; Study Guinea: Jan 2015/Oxford

• Cocktail of 3 monoclonal antibodies

• 100% protective in NPH up to 5 days post-challenge

• Used in a few human cases

• Few doses available

• 3 IV administrations with 3 days interval

20

EVD in USA: ZMapp

Lyon GM et al. N Engl J Med 2014

21

EVD vaccines

cAd3 EBOV GP (GSK) Phase 1 ongoing

rVSV EBOV GP (NewLink Genetics) Phase 1 ongoing

22

EVD epidemic: new and total cases, Dec 10, 2014

WHO roadmap Dec 10, 2014.

+/- 18000 cases

23

EVD epidemic: cases weekly reported: recent trends

WHO roadmap Dec 10, 2014

Liberia Sierra Leone

Guinea

Case fatality rate • Total: 75 % • Hospital: 60 %

• Post conflict environment in affected countries

• Porous borders between countries

• First epidemic in urban setting

• Extensive mobility and air travel in West Africa

• Inefficient healthcare system

• Traditional burial practices

• Negative cultural practices and traditional beliefs

• First occurrence of Ebola in West Africa (no institutional memory)

• Health workers not trained to respond and protect themselves

• Inadequate and late international response

• High level of resistance to the Ebola outbreak response

Current EVD in West Africa: why so different ?

• Largest and most persistent EVD outbreak ever

• Widespread under-reporting of new cases

• No persuasive evidence that the epidemic is under control

• Low but existing risk of importation to Belgium

Current EVD in West Africa: conclusions

Bedankt voor uw aandacht

26

Recommended